Development, Characterization and In Vivo Pharmacokinetic Assessment of Rectal Suppositories Containing Combination Antiretroviral Drugs for HIV Prevention
Authors:
- Kunal JhunjhunwalaKJKunal Jhunjhunwala
- Charles W. DobardCDCharles W. Dobard
- Sunita SharmaSSSunita Sharma
- Natalia MakarovaNMNatalia Makarova
- Angela HolderAHAngela Holder
- Chuong DinhCDChuong Dinh
- James MitchellJMJames Mitchell
- Lin WangLWLin Wang
- Junmei ZhangJZJunmei Zhang
- Sravan Kumar PatelSravan Kumar Patel
- Walid HeneineWHWalid Heneine
- Lisa C. RohanLisa C. Rohan
Open Access
- 21 July 2021
- journal article
- research article
- Published by MDPI AG in Pharmaceutics
- Vol. 13 (8) , 1110
Abstract
Receptive anal intercourse (RAI) contributes significantly to HIV acquisition underscoring the need to develop HIV prevention options for populations engaging in RAI practices. We explored the feasibility of formulating rectal suppositories with potent antiviral drugs for on-demand use. A fixed-dose combination of tenofovir (TFV) and elvitegravir (EVG) (40 mg each) was co-formulated in six different suppository bases (three fat- and three water-soluble). Fat-soluble witepsol H15 and water-soluble polyethylene glycol (PEG) based suppositories demonstrated favorable in vitro release and were advanced to assess in vivo pharmacokinetics following rectal administration in macaques. In vivo drug release profiles were similar for both suppository bases. Median concentrations of TFV and EVG detected in rectal fluids at 2 h were 1- and 2-logs higher than the in vitro IC50, respectively; TFV-diphosphate levels in rectal tissues met or exceeded those associated with high efficacy against rectal simian HIV (SHIV) exposure in macaques. Leveraging on these findings, a PEG-based suppository with a lower dose combination of tenofovir alafenamide (TAF) and EVG (8 mg each) was developed and found to achieve similar rectal drug exposures in macaques. This study establishes the utility of rectal suppositories as a promising on-demand strategy for HIV PrEP and supports their clinical development.Keywords
This publication has 32 references indexed in Scilit:
- Antiviral Activity, Safety, and Pharmacokinetics/Pharmacodynamics of Tenofovir Alafenamide as 10-Day Monotherapy in HIV-1–Positive AdultsJAIDS Journal of Acquired Immune Deficiency Syndromes, 2013
- Rectal Microbicide Development2013
- RMP-02/MTN-006: A Phase 1 Rectal Safety, Acceptability, Pharmacokinetic, and Pharmacodynamic Study of Tenofovir 1% Gel Compared with Oral Tenofovir Disoproxil FumarateAIDS Research and Human Retroviruses, 2012
- Pharmacokinetics of Tenofovir following Intravaginal and Intrarectal Administration of Tenofovir Gel to Rhesus MacaquesAntimicrobial Agents and Chemotherapy, 2012
- Self-Microemulsifiyng Suppository Formulation of β-ArtemetherAAPS PharmSciTech, 2010
- In Vitro and Ex Vivo Testing of Tenofovir Shows It Is Effective As an HIV-1 MicrobicidePLOS ONE, 2010
- Vaginal microbicides and the prevention of HIV transmissionThe Lancet Infectious Diseases, 2008
- The Natural History of Primary Hyperparathyroidism with or without Parathyroid Surgery after 15 YearsThe Journal of Clinical Endocrinology & Metabolism, 2008
- Prevention of SIV Rectal Transmission and Priming of T Cell Responses in Macaques after Local Pre-exposure Application of Tenofovir GelPLOS Medicine, 2008
- Microbicides: A new frontier in HIV preventionBiologicals, 2006